Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial - PubMed
4 hours ago
- #Chemoimmunotherapy
- #Follicular Lymphoma
- #Long-term Follow-up
- 15-year follow-up data from the SWOG S0016 trial evaluated long-term remission and cure in follicular lymphoma (FL) patients treated with CHOP-based chemoimmunotherapy.
- The study included 531 patients randomized to receive either R-CHOP or CHOP-RIT, with a median follow-up of 15.5 years.
- Overall 15-year survival was 70%, with no significant difference between treatment arms, but CHOP-RIT showed superior 15-year progression-free survival (47% vs 34%).
- Cure modeling estimated a 42% overall cure rate, higher in patients with low Follicular Lymphoma International Prognostic Index scores and normal β2 microglobulin levels.
- Relapse rates declined substantially over time, from 6.8% in the first 5 years to 0.6% between 15 to 20 years, suggesting potential cure in a subset of FL patients.